Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Stacie Hudgens's publication output changed over time?
ScholarIQpublication output · 2002–2021
Output grew0% over the shown period — from 1 works in 2002 to 1 in 2021.
1
2
1
1
3
1
1
2002200320152017201820202021
What are the most-cited papers on Stacie Hudgens?
ScholarIQmost cited works
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, Alain H. Rook, Pierluigi Porcu, Sarah McCue Horwitz, Sean Whittaker, Y. Tokura, Maarten H. Vermeer, Pier Luigi Zinzani, Lubomir Sokol, Stephen Morris, Ellen J. Kim, Pablo L. Ortiz‐Romero, Herbert Eradat, Julia Scarisbrick, Athanasios Tsianakas, Craig A. Elmets, Stéphane Dalle, David C. Fisher, Ahmad Halwani, Brian Poligone, John P. Greer, Maria Teresa Fierro, Amit Khot, Alison J. Moskowitz, Amy Musiek, Andrei R. Shustov, Barbara Pro, Larisa J. Geskin, Karen M. Dwyer, Junji Moriya, Mollie Leoni, Jeffrey S. Humphrey, Stacie Hudgens, Dmitri O. Grebennik, Kensei Tobinai, Madeleine Duvic, Sunil Abhyankar, Oleg E. Akilov, Önder Alpdoğan, M. Beylot‐Barry, Erin Boh, Dolores Caballero, Richard Cowan, Brigitte Dréno, Reinhard Dummer, Timothy S. Fenske, Francine Foss, Noriko Fukuhara, Pratyush Giri, Koji Habe, Toshihisa Hamada, Kiyohiko Hatake, Shinsuke Iida, Osamu Ishikawa, Lars Iversen, Eiji Kiyohara, Hiroshi Koga, Neil J. Korman, Bryone J. Kuss, Zanetta S. Lamar, Frederick Lansigan, Mary Jo Lechowicz, Adam Lerner, Nina Magnolo, Lawrence A. Mark, Tomomitsu Miyagaki, Javier Muñoz, Jan P. Nicolay, Kaoru Nishiwaki, Hiroyuki Okamoto, Mikio Ohtsuka, Theresa Pacheco, Christiane Querfeld, Ronald Peter Rapini, Shigetoshi Sano, Maiko Tanaka, Michael D. Tharp, Jiro Uehara, Hidefumi Wada, Jillian Wells, Ryan A. Wilcox, Basem M. William, Kentaro Yonekura
The Lancet Oncology. 2018660 CitationsOPEN ACCESS
Measuring the side effects of taxane therapy in oncology
David Cella, Amy H. Peterman, Stacie Hudgens, Kimberly Webster, Mark A. Socinski
Cancer. 2003289 Citations
Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study
Elizabeth A. Hahn, G. Alastair Glendenning, Mark Sorensen, Stacie Hudgens, Brian Druker, François Guilhot, Richard A. Larson, Stephen G. O’Brien, Deborah Dobrez, Martee L. Hensley, David Cella
Journal of Clinical Oncology. 2003209 Citations
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
Arndt Vogel, Shukui Qin, Masatoshi Kudo, Yun Su, Stacie Hudgens, Tatsuya Yamashita, Jung‐Hwan Yoon, Lætitia Fartoux, Krzysztof Simon, Carlos López, Max W. Sung, Kalgi Mody, Tatsuroh Ohtsuka, Toshiyuki Tamai, L. Michelle Bennett, Genevieve Meier, Valery Breder
The Lancet. Gastroenterology & hepatology. 2021153 Citations
Atherosclerotic risk factor reduction in peripheral arterial disease
Mary Mcdermott, Elizabeth A. Hahn, Philip Greenland, David Cella, Judith K. Ockene, Donna Brogan, William H. Pearce, Alan T. Hirsch, Kendra Hanley, Linda Odom, Shaheen Khan, Michael H. Criqui, Martin S. Lipsky, Stacie Hudgens
Journal of General Internal Medicine. 2002130 CitationsOPEN ACCESS
Related on ScholarIQ
Health Outcomes Solutions (United States)
Institution
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Paper
Measuring the side effects of taxane therapy in oncology
Paper
Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study
Paper
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
Paper
Atherosclerotic risk factor reduction in peripheral arterial disease
Paper